We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
-17.36%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.96B
AUM Growth
-$443M
Cap. Flow
+$513M
Cap. Flow %
17.33%
Top 10 Hldgs %
65.6%
Holding
45
New
14
Increased
9
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$83.3M
2
XLRN
Acceleron Pharma
XLRN
+$66.8M
3
PTCT icon
PTC Therapeutics
PTCT
+$60.4M
4
SAGE
Sage Therapeutics
SAGE
+$57.9M
5
RLMD icon
Relmada Therapeutics
RLMD
+$46.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.1M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$6.73M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.26M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.03M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
26
Aurinia Pharmaceuticals
AUPH
$2.15B
$25M 0.84%
+1,725,000
New +$30.4M
MDGL icon
27
Madrigal Pharmaceuticals
MDGL
$12.1B
$23.3M 0.79%
349,000
– –
ALLO icon
28
Allogene Therapeutics
ALLO
$594M
$21.9M 0.74%
1,128,594
– –
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$20M 0.68%
+4,950,000
New +$18.7M
BDTX icon
30
Black Diamond Therapeutics
BDTX
$113M
$13M 0.44%
+521,750
New +$15.9M
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.6M 0.42%
1,550,000
– –
BDSI
32
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$11.4M 0.38%
3,000,000
– –
RVMD icon
33
Revolution Medicines
RVMD
$43.9B
$9.86M 0.33%
+450,000
New +$12.5M
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
$8.14M 0.27%
5,500,000
– –
AMRN
35
Amarin Corp
AMRN
$294M
$8M 0.27%
100,000
+5,000
+5% +$1.66M
TGTX icon
36
TG Therapeutics
TGTX
$8.12B
$7.87M 0.27%
800,000
-200,000
-20% -$2.53M
AGEN
37
Agenus
AGEN
$322M
$6.74M 0.23%
+140,113
New +$8.8M
FENC icon
38
Fennec Pharmaceuticals
FENC
$373M
$6.57M 0.22%
1,105,999
– –
IMGN
39
DELISTED
Immunogen Inc
IMGN
$6.48M 0.22%
+1,900,000
New +$8.31M
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.61B
$6.13M 0.21%
+145,000
New +$5.97M
IOVA icon
41
CALL
Iovance Biotherapeutics
IOVA
$4.24B
$3.13M 0.11%
+1,250,000
New +$33.1M
ALIM
42
DELISTED
Alimera Sciences
ALIM
$1.6M 0.05%
415,999
– –
AMRN
43
CALL
Amarin Corp
AMRN
$294M
$10K ﹤0.01%
+50,000
New +$16.6M
DCPH
44
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-800,000
Closed -$5.01M
SGEN
45
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-75,000
Closed -$150K
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Avoro Capital Advisors held 45 positions worth $2.96B, down 13% from $3.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $513M of net new capital in Q1 2020, opening 14 new positions and adding to 9 existing holdings. Its largest new stake was Acceleron Pharma: 860,000 shares worth $77.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20M trimmed.

  • Avoro Capital Advisors's largest Q1 2020 buy was Acceleron Pharma: 860,000 shares worth $77.3M.
  • Avoro Capital Advisors added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $83.3M increase.
  • Avoro Capital Advisors's biggest Q1 2020 reduction was Sarepta Therapeutics, cutting an estimated $20M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $2.96B portfolio in Q1 2020.
  • Avoro Capital Advisors opened 14 new positions and closed 2 in Q1 2020.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $2.96B.

Based on Avoro Capital Advisors's 13F filing for Q1 2020, filed 15 May 2020.